- Home
- RRR vs CORT Comparison
RRR vs CORT Comparison
Compare RRR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | CORT |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RRR | CORT |
|---|---|---|
| Price | $57.12 | $34.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $66.46 | ★ $105.20 |
| AVG Volume (30 Days) | 746.6K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 3.12 | 0.82 |
| Revenue | ★ $2,011,483,000.00 | $761,407,000.00 |
| Revenue This Year | $3.26 | $26.08 |
| Revenue Next Year | $4.48 | $31.04 |
| P/E Ratio | ★ $19.20 | $41.63 |
| Revenue Growth | 3.74 | ★ 12.79 |
| 52 Week Low | $35.09 | $28.66 |
| 52 Week High | $68.99 | $117.33 |
Technical Indicators
Market Signals| Indicator | RRR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 44.07 |
| Support Level | $55.56 | $34.06 |
| Resistance Level | $61.64 | $41.92 |
| Average True Range (ATR) | 2.02 | 1.27 |
| MACD | -0.03 | 0.48 |
| Stochastic Oscillator | 26.59 | 62.89 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.